NSE
AstraZeneca Pharma India LimitedASTRAZEN
AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca focused on pharmaceuticals in India.
| Key products | Specializes in biopharmaceuticals, oncology, respiratory, and autoimmunity products. |
|---|---|
| Geography | Primarily operates in the Indian market with regional presence. |
| Competitors | Cipla Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹12.8 Cr | 131 | — | — | — | — |
| 2 | ASTRAZENThis | — | — | — | — | — | — |
| 3 | MOBIKWIK | +₹0 Cr | 60 | — | — | — | — |
| 4 | QUADFUTURE | +₹0 Cr | 34 | — | — | — | — |
| 5 | MTNL | — | — | — | — | — | — |
| 6 | GATECH | +₹0 Cr | 6 | — | — | — | — |
| 7 | IRMENERGY | −₹2.2 Cr | 328 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Strong pipeline of innovative biopharmaceuticals
- • Diversified revenue streams across multiple therapeutic areas
- • Established presence in India with a large distribution network
- • Growing presence in emerging markets
Weaknesses
- • Dependence on a few key products
- • High research and development expenses
- • Competition from generic and biosimilar products
- • Regulatory challenges in emerging markets
Opportunities
- • Increasing demand for biopharmaceuticals in India
- • Growing market for respiratory and autoimmunity therapies
- • Expansion into new therapeutic areas such as immunology
- • Partnerships with pharmaceutical companies to access new markets
Threats
- • Genericization of branded products
- • Competition from low-cost biosimilars
- • Regulatory changes in key markets
- • Economic fluctuations affecting consumer spending
AI-generated from our data — verify before relying on it.
- 2026-06-16FilingAstraZeneca Pharma India Limited has informed the Exchange about General UpdatesGeneral
- 2026-06-15FilingAstraZeneca Pharma India Limited has informed the Exchange regarding the Trading Window closure pursuant to SECompliance
- 2026-06-13FilingAstraZeneca Pharma India Limited has informed the Exchange about Resignation of Director/KMP/SMPRisk
- 2026-06-12FilingAstraZeneca Pharma India Limited has informed the Exchange about General UpdatesGeneral
- 2026-06-11FilingAstraZeneca Pharma India Limited has informed the Exchange about General UpdatesGeneral
- 2026-06-09FilingAstraZeneca Pharmaceuticals AB has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of thShareholding Disclosure
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2
- 1ComplianceNeutral
the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Source PDF → - 3
- 2
- 2
- 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF →
No bulk/block deals for ASTRAZEN in this window.
News & chatter on ASTRAZEN
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.